johnson & johnson news

Johnson & Johnson Dips On Q4 Earnings

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

The Motley Fool · 4d

Johnson & Johnson Tops Q4 EPS Forecasts

Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations. Johnson & Johnson is a diversified healthcare giant ...

Yahoo Finance · 4d

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...

Bears hire Ben Johnson

USA TODAY Touchdown Wire o… · 1d

Ben Johnson promises Bears will make QB history during his tenure

During his introductory press conference, Johnson vowed to get the Bears to the playoffs next season, and in a recent interview, he proclaimed that Bears franchise history would b

Chicago Tribune on MSN · 1d

Antwaan Randle El headed home to join new coach Ben Johnson’s staff with the Bears

Ben Johnson is making progress building his staff two days after he was introduced as coach of the Chicago Bears. The former Lions offensive coordinator is bringing two assistants with him from Detroit.

CBS Sports on MSN · 1d

Bears' Ben Johnson continues adding to his staff, poaching coaches from the Lions and Cowboys, per reports

Ben Johnson is quickly building his first coaching staff as the Bears head coach, and he's poaching from a few other teams in the process. The Bears are working to finalize a deal with Lions receivers coach Antwaan Randle El to be their new assistant head coach/wide receivers coach,

“Johnson & Johnson: Buy Rating Reaffirmed Despite Price Target Cut, Growth Prospects Highlighted”

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

2don MSN

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

MassDevice4d

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

4don MSN

Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness

Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results